Page 2244 - Williams Hematology ( PDFDrive )

2218 Part XII: Hemostasis and Thrombosis Chapter 129: Disseminated Intravascular Coagulation 2219

all randomized, placebo-controlled, double-blind trials with antithrombin III in severe 337. Pernerstorfer T, Hollenstein U, Hansen JB, et al: Lepirudin blunts endotoxin-induced
sepsis. Intensive Care Med 24:663, 1998. coagulation activation. Blood 95:1729, 2000.
325. Baudo F, Caimi TM, de CF, et al: Antithrombin III (ATIII) replacement therapy in 338. Feinstein DI: Diagnosis and management of disseminated intravascular coagulation:
patients with sepsis and/or postsurgical complications: A controlled double-blind, ran- The role of heparin therapy. Blood 60:284, 1982.
domized, multicenter study. Intensive Care Med 24:336, 1998. 339. Levi M, Levy M, Williams MD, et al: Prophylactic heparin in patients with severe sepsis
326. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 176:483, 2007.
antithrombin III in severe sepsis: A randomized controlled trial. JAMA 286:1869, 340. Vlasuk GP, Bergum PW, Bradbury AE, et al: Clinical evaluation of rNAPc2, an inhibitor
2001. of the fVIIa/tissue factor coagulation complex. Am J Cardiol 80:66S, 1997.
327. Lavrentieva A, Kontakiotis T, Bitzani M, et al: The efficacy of antithrombin administra- 341. Abraham E, Reinhart K, Svoboda P, et al: Assessment of the safety of recombinant tis-
tion in the acute phase of burn injury. Thromb Haemost 100:286, 2008. sue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized,
328. Levi M: Activated protein C in sepsis: A critical review. Curr Opin Hematol 15:481, placebo-controlled, single-blind, dose escalation study. Crit Care Med 29:2081, 2001.
2008. 342. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant
329. Bernard GR, Ely EW, Wright TJ, et al: Safety and dose relationship of recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA
human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29:2051, 290:238, 2003.
2001. 343. Saito H, Maruyama I, Shimazaki S, et al: Efficacy and safety of recombinant human sol-
330. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human uble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of
activated protein C for severe sepsis. N Engl J Med 344:699, 2001. a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5:31, 2007.
331. Vincent JL, Angus DC, Artigas A, et al: Effects of drotrecogin alfa (activated) on organ 344. Gralnick HR, Greipp P: Thrombosis with epsilon aminocaproic acid therapy. Am J Clin
dysfunction in the PROWESS trial. Crit Care Med 31:834, 2003. Pathol 56:151, 1971.
332. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe 345. Naeye RL: Thrombotic state after a hemorrhagic diathesis, a possible complication of
sepsis and a low risk of death. N Engl J Med 353:1332, 2005. therapy with epsilon-aminocaproic acid. Blood 19:694, 1962.
333. Laterre PF: Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care 11 346. Mannucci PM, Levi M: Prevention and treatment of major blood loss. N Engl J Med
Suppl 5:S5, 2007. 356:2301, 2007.
334. Ranieri VM, Thompson BT, Barie PS, et al: Drotrecogin alfa (activated) in adults with 347. Minna JD, Robboy SJ, Colman RW: Disseminated Intravascular Coagulation in Man.
septic shock. N Engl J Med 366:2055-, 2012. Charles C Thomas, Springfield, IL, 1974.
335. Thachil J, Toh CH, Levi M, Watson HG: The withdrawal of activated protein C from 348. Matsuda M, Aoki N: Statistics on underlying and causative diseases of DIC in Japan, in
the use in patients with severe sepsis and DIC [amendment to the BCSH guideline on Disseminated Intravascular Coagulation, edited by T Abe, M Yamanake, p 15. Karger,
disseminated intravascular coagulation]. Br J Haematol 157:493, 2012. Basel, 1983.
336. du Toit H, Coetzee AR, Chalton DO: Heparin treatment in thrombin-induced dissem- 349. Larcan A, Lambert H, Gerard A: Consumption Coagulopathies. Masson, New York,
inated intravascular coagulation in the baboon. Crit Care Med 19:1195, 1991. 1987.

Kaushansky_chapter 129_p2199-2220.indd 2219 17/09/15 3:46 pm